Viatris Inc. Common Stock (VTRS) Financial Statements
Historical financial data — 24 statements covering FY2020–FY2025
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that...
Viatris Inc. Common Stock's revenue decreased 3.0% year over year, from $14.74B to $14.30B.
Net income decreased 454.2% over the same period, from $-634.2M to $-3.51B.
Over the 5-year period from FY2020 to FY2025, revenue grew by 20% in total.
Total debt decreased by 11.1% to $12.48B.
The debt-to-equity ratio stands at 0.85, indicating a moderate leverage profile.
Operating cash flow grew 0.6% to $2.32B.
Viatris Inc. Common Stock maintains a negative net profit margin of -24.6%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2023 | $7.65B-38.3% | $488.7M | $3.15B | $769.0M | $1.49B | $48.70B | $17.27B | $20.84B |
| Q3 FY2023 | $11.59B+51.5% | $820.3M | $4.84B | $1.22B | $2.32B | $48.74B | $17.08B | $20.87B |
| Q1 FY2024 | $3.66B-68.4% | $113.9M | $1.50B | $203.9M | $614.6M | $47.34B | $16.07B | $20.01B |
| Q3 FY2024 | $11.21B+206.0% | $-117.7M | $4.41B | $189.9M | $1.82B | $44.75B | $14.30B | $19.79B |
| Q1 FY2025 | $3.25B-71.0% | $-3.04B | $1.16B | $-2.88B | $535.5M | $38.47B | $14.18B | $15.65B |
| Q2 FY2025 | $6.84B+110.1% | $-3.05B | $2.49B | $-2.65B | $755.2M | $38.41B | $12.79B | $15.57B |
| Q3 FY2025 | $10.60B+55.0% | $-3.17B | $3.87B | $-2.47B | $1.50B | $37.92B | $12.49B | $15.22B |
| Q1 FY2026 | $3.52B-66.8% | $176.4M | $1.16B | $-79.7M | $388.3M | $36.83B | $12.41B | $14.66B |
Balance Sheet Summary (Latest Period)
Total Assets
$37.19B
Total Liabilities
$22.48B
Total Equity
$14.71B
Cash & Equivalents
$1.32B
Total Debt
$12.48B
Current Assets
$9.79B
Current Liabilities
$7.09B
Retained Earnings
$-388.3M